Cargando…

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular Dystrophy

Suppression of the myostatin (GDF‐8) pathway has emerged as an important therapeutic paradigm for muscle‐wasting disorders. In this study, we conducted a translational pharmacokinetic/pharmacodynamic (PK/PD) analysis of MYO‐029, an anti‐myostatin monoclonal antibody, using PK data in mice, rats, mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, P, Rong, H, Gordi, T, Bosley, J, Bhattacharya, I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351001/ https://www.ncbi.nlm.nih.gov/pubmed/27700008 http://dx.doi.org/10.1111/cts.12420

Ejemplares similares

Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies
por: Finley, Stacey D, et al.
Publicado: (2011)

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
por: Haraya, Kenta, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
por: Leipold, Douglas, et al.
Publicado: (2018)

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation
por: Salvadori, Michela, et al.
Publicado: (2019)

Current Translational Research and Murine Models For Duchenne Muscular Dystrophy
por: Rodrigues, Merryl, et al.
Publicado: (2016)

Translating golden retriever muscular dystrophy microarray findings to novel biomarkers for cardiac/skeletal muscle function in Duchenne Muscular Dystrophy
por: Galindo, Cristi L., et al.
Publicado: (2015)

P01-029 – Microscopic hematuria in FMF
por: Grabowitz, L, et al.
Publicado: (2013)

SPSC - list of members - 89-029
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1989)

Opération piquet PO 2000-029
por: Royer, J P
Publicado: (2000)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029
por: Bonnet, Mathilde, et al.
Publicado: (2019)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
por: Lledo‐Garcia, Rocio, et al.
Publicado: (2021)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

A translational approach to dystroglycanopathies: a frequent type of muscular dystrophy
por: Cirak, Sebahattin, et al.
Publicado: (2015)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Saying NO to muscular dystrophy
por: Dove, Alan W.
Publicado: (2001)

Fatigue in muscular dystrophies
por: Angelini, Corrado, et al.
Publicado: (2012)

RNAseq analysis for the diagnosis of muscular dystrophy
por: Gonorazky, Hernan, et al.
Publicado: (2015)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans
por: Ruigrok, Mitchel J. R., et al.
Publicado: (2015)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Differential Diagnosis between Duchenne Muscular Dystrophy and Limb Girdle Muscular Dystrophy 2a
por: DOBRESCU, M.A., et al.
Publicado: (2015)

Cardiac Dysrhythmias, Cardiomyopathy and Muscular Dystrophy in Patients with Emery-Dreifuss Muscular Dystrophy and Limb-Girdle Muscular Dystrophy Type 1B
por: Hong, Jong-Seo, et al.
Publicado: (2005)

Editorial: Pathophysiological Mechanisms of Sarcopenia in Aging and in Muscular Dystrophy: A Translational Approach
por: Merlini, Luciano, et al.
Publicado: (2015)

Identifying the hub genes for Duchenne muscular dystrophy and Becker muscular dystrophy by weighted correlation network analysis
por: Wang, Junjie, et al.
Publicado: (2021)

Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
por: Trifunov, Selena, et al.
Publicado: (2020)

Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network
por: Kang, Peter B., et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
por: Wang-Lin, Shun Xin, et al.
Publicado: (2018)

Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
por: Tang, Yu, et al.
Publicado: (2021)

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab
por: Lindauer, A, et al.
Publicado: (2016)

Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2018)

Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients
por: Capitanio, Daniele, et al.
Publicado: (2020)

Exopolysaccharides and Antimicrobial Biosurfactants Produced by Paenibacillus macerans TKU029
por: Liang, Tzu-Wen, et al.
Publicado: (2013)

Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse
por: Teich, Andrew F., et al.
Publicado: (2018)

Looking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies
por: Bushby, Kate
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9r99jstu2qh14vtlq75vh30g4a